GSK and Sanofi’s COVID-19 vaccine delivered strong rates of neutralising antibody responses

GlaxoSmithKline and Sanofi have proclaimed that their COVID-19 vaccine, which has been delayed, delivered strong rates of neutralising antibody responses in a mid-stage trial.

The Phase II trial was built up of seven hundred and twenty-two participants in Honduras and the US. It included similar figures of adults aged eighteen to fifty-nine, as well as those aged sixty and above.

The adjuvanted recombinant protein-based vaccine produced by Sanofi and GlaxoSmithKline obtained immune responses comparable to those seen in those who have recovered from COVID-19.

Moreover, the interim results conveyed a ninety-five to one hundred per cent seroconversion, following a second injection in all adult age groups in the trial and throughout all doses.

Before COVID-19 infection, high neutralising antibody titres were witnessed in participants, implying the vaccine candidate could have the potential to be used as a booster vaccine.

President of GSK Vaccines, Roger Connor, stated: “[The] positive data shows the potential of this protein-based adjuvanted vaccine candidate in the broader context of the pandemic, including the need to address variants and to provide for booster doses. We believe that this vaccine candidate can make a significant contribution to the ongoing fight against COVID-19 and will move to Phase III as soon as possible to meet our goal of making it available before the end of the year.”